Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe Mounjaro shot begins acting on GIP and GLP-1 receptors within hours of injection, but the weight-loss effects you can feel — reduced appetite, smaller portions feeling satisfying — typically build over the first two to four weeks at each dose. Most people notice early appetite changes within a few days; meaningful weight change usually shows by weeks four to eight. That said, tirzepatide is a prescription-only medicine and the right dose, timing and expectations are set by a prescriber after a clinical assessment, not by a standard answer on a webpage. If you have just taken your first pen and are wondering whether it is doing anything yet, you are in good company. That particular week-one uncertainty is one of the things our prescribers hear most often.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
You injected the pen. Nothing dramatic happened. That is completely normal, and it does not mean the medicine is inert.
Tirzepatide is absorbed gradually from the subcutaneous tissue, fat just under the skin at the abdomen, thigh or upper arm. Peak plasma concentration arrives somewhere between 24 and 72 hours after the shot, then falls slowly across the rest of the week before the next dose. Because the medicine has a long half-life of roughly five days, it does not arrive fast and leave fast the way some tablets do. It builds a steady presence.
During those first hours it is already binding to GIP and GLP-1 receptors, slowing gastric emptying and beginning to modulate the appetite signals your brain receives. Some people feel a faint nausea or a slightly earlier sense of fullness during the first meal after their first shot. Others feel nothing at all in week one. Both are within the expected range. For a broader overview of how the medicine works and what it is licensed for, the Mounjaro treatment page covers the mechanism in more detail.
The NHS tirzepatide patient information notes that common early effects are gastrointestinal (nausea, indigestion, burping) and that these generally settle as the body adapts. You can read the full list of side effects on the NHS tirzepatide medicines page.
This is where most people start to notice something is genuinely different.
After the second or third weekly shot, the cumulative drug level is higher and more stable. Gastric emptying slows enough that a moderate portion feels like a large one. The internal pressure to snack between meals (the one most people thought was just their personality) begins to quieten. For some this is striking; for others it is more of a gradual drift toward eating less without fighting it.
At the 2.5 mg starter dose, appetite effects are often mild. The dose exists to settle your digestive system into the medicine's rhythm. Once a prescriber moves you up, the appetite signal typically sharpens. The SURMOUNT-1 trial, published in the New England Journal of Medicine, showed that participants lost weight progressively across the full 72-week period, with losses accumulating dose by dose rather than arriving all at once at a specific week.
If you are wondering how long after taking Mounjaro you can expect it to start working, the answer depends heavily on which dose you are currently at and how many weeks of titration you have completed. If something feels genuinely wrong rather than just slow, speak to your prescriber or contact our team through the support page.
The numbers people cite (average losses of around 20% of body weight at the highest dose over 72 weeks) come from a sustained, cumulative process. There is no single shot at which tirzepatide "kicks in" the way a painkiller does. The mechanism is more like a dial being gradually turned.
Appetite suppression compounds. People begin restructuring meals naturally, eating protein-forward portions, stopping sooner. Physical activity often increases simply because carrying less weight is easier. None of this shows up on a scale in week one.
Several factors affect the pace: the dose you are currently at, how your body metabolises the medicine, your diet and activity alongside it, and whether any other medicines are interacting with absorption. If your results feel slower than expected, our page on how long Mounjaro takes to work sets out a realistic timeline by dose and week so you can benchmark your experience against the clinical evidence. If belly fat specifically seems stubborn despite overall losses, the page on why belly fat can lag behind on tirzepatide addresses that directly, visceral fat responds to the same mechanism but on its own timeline.
The full trial evidence is also covered in our summary of SURMOUNT-1 results if you want the figures in context. For a sense of how costs fit into a multi-month journey, the Mounjaro price page explains what is included in private treatment and what to look for in any quote.
A reasonable check-in point is 12 weeks at the highest tolerated dose. NICE's appraisal of tirzepatide, TA1026, notes that continuing treatment is reviewed if body-weight loss is less than 5% after six months at the highest dose a person can tolerate. That is the clinical benchmark, not a four-week snapshot.
Some concerns do warrant earlier contact with a prescriber. Severe stomach pain that spreads toward the back, with or without vomiting, should be assessed urgently, that is the symptom profile linked to pancreatitis, which the MHRA highlighted in a 2026 drug safety communication. Persistent vomiting, signs of dehydration, or any symptom that feels serious rather than uncomfortable are reasons to call a clinician the same day. For anything that can wait, our prescribers are available seven days a week through the aftercare channel.
If you are considering starting treatment and want a same-day clinical review from a GPhC-registered prescriber, you can start your free consultation at any point.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.